Phathom Pharmaceuticals Inc PHAT
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-10-25 |
| Shares Out. | 79,760,000 |
| Website | phathompharma.com/ ↗ |
| Phone | 13026365400 |
| Employees | 371 |
| Revenue | $74.3M |
| Gross Profit | $59.2M |
| Net Income | -$17.6M |
| Free Cash Flow | -$36.9M |
| Total Assets | $327.1M |
| Total Liabilities | $671.3M |
| Equity | -$344.3M |
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Phathom Pharmaceuticals Inc is a publicly traded company under the ticker symbol PHAT on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-09-01)